Trials soon ready
Clinical trials expected to report results within the next 6 months, ranked by how much the coming result could matter. Each trial shows its estimated finish date, explained in plain language.
This page shows companies working on cures and vaccines first, on purpose. We believe investor interest in cures leads to more cure trials. Why we do this.
Showing the top 50 of 21426 trials in this window.
Results due in the coming weeks
These trials are in their final phase, the companies running them are on the stock market, and results are due within weeks. A final-phase result is usually the last big test before a treatment can be approved, and it can move the company's value in either direction. We list them up top so you see the nearest dates first.
-
Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread Results expected Sep 2026 (estimated) 🚀 Make-or-breakClarity Pharmaceuticals Ltd ASX: CU6
-
New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
Rabies vaccine batch check: will it pass the test? Results expected Sep 2026 (estimated) 🚀 Make-or-breakSinovac Biotech Co., Ltd. NASDAQ: SVA
The weekly investor briefing
One email every Sunday: which trial results are due in the coming weeks, what read out in the past week, and the small companies with a make-or-break result ahead. Free, and every issue has a one-click unsubscribe.
We'll send one confirmation email first — you're not subscribed until you click it.
-
One-Time gene therapy aims to restore muscle in boys with duchenne
Disease control OngoingRGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, …
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
Result impact 🚀 Make-or-breakVery highSmall-cap Phase 3, decisive Readout dueA result this decisive could redraw a company this size.
RegenxBio Inc. · RGNX NASDAQ Trade on eToro (ad)Why investors are watching
RegenxBio is testing RGX-202, a one-time gene therapy for Duchenne muscular dystrophy, in a 65-patient study that combines phase 2 and phase 3. For a small company, this trial is the main driver of its value, because a positive result could support regulatory approval and a negative result would leave it without a clear path forward.
If it works: If RGX-202 shows it is safe and helps boys with Duchenne, RegenxBio could move closer to bringing the therapy to market. That outcome would validate the company's core science and give it a product to sell.
If it fails: Gene therapy trials often fail on safety or effectiveness, and this one is still in early testing. A failure or delay could leave RegenxBio with no approved product and little reason for investors to stay.
AI-written from the trial record. Speculative, and not investment advice.
-
Can a shorter radiation course spare the rectum in rectal cancer?
Cure OngoingThe hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to directly compare the newly established TNT concepts applying either short-course RT according to RAPIDO, or CRT according to CAO/ARO/AIO-04/-12, both followed by consolidation chemotherapy, and surgery or a watch\&wait…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Prof. Dr. med. Claus Rödel • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
One shot, six months of malaria shield? a new trial tests a powerful antibody in children
Prevention OngoingBackground and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge. In highly malaria-endemic settings, malaria is a major contributor to these post-discharge readmissions and de…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
New hope for kids with blood cancer: tailored treatments aim to boost cure rates and cut side effects
Disease control OngoingThe overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (A…
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Result impactModerateLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
Could a Virus-Like particle vaccine outsmart polio?
Vaccine OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 08, 2026 00:03 UTC
Result impactVery highSmall-cap Phase 2 Readout in ~1 wkA small company. This result carries real weight for it.
CanSino Biologics Inc. · 6185 HKEXWhy investors are watching
CanSino Biologics is testing a new polio vaccine that uses virus-like particles instead of the traditional live or inactivated virus. This trial checks the vaccine's safety and immune response in infants and toddlers, and a positive result could give the small company a new product in a global market with steady demand. Because CanSino is small, this single trial's outcome can meaningfully affect its value and reputation.
If it works: A successful readout could position CanSino as a leader in next-generation polio vaccines, potentially opening partnerships or licensing deals with larger organizations. It may also validate the company's VLP platform for other vaccines, broadening its pipeline.
If it fails: The trial could fail to show adequate immune response or safety, which would set back the program and hurt investor confidence. Trials at this stage often fail, and any delay in enrollment or dosing could also weigh on the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
-
Could a stem cell transplant cure immune diseases?
Cure Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Results expected Oct 2026 (estimated)
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can specially trained immune cells flush out hidden HIV?
Cure OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Results expected Nov 2026 (estimated)
Phase 1 • Sponsor: Catherine Bollard • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThe purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical respon…
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 2 Readout in ~6 wkA large company. One readout moves the needle only so far.
-
New hope for advanced breast cancer: targeted drug combo tested in major trial
Disease control OngoingThe study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
May already have reported ↗ AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap May already have reported Readout in ~2 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-03-16 → -
New hope for kids with leukemia: smarter chemo dosing could boost cures
Cure OngoingAcute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous ly…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Dana-Farber Cancer Institute • Aim: Cure
Last updated Jul 18, 2026 00:00 UTC
-
One-Time gene shot aims to stop bleeding in hemophilia a
Disease control Recruiting nowThis study is a single-arm, open-label, multicenter study evaluating the efficacy and safety of GS1191-0445 injection as a single dose in Chinese subjects with hemophilia A. GS1191-0445 is an AAV8-based gene therapy vector designed to express B-domain deleted human factor VIII (…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Gritgen Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can a single radiation dose cure large liver tumors?
Cure Recruiting nowThe RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in pa…
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lung cancer
Cure Recruiting nowA study to evaluate the safety and feasibility of α-PD-L1/4-1BB DLL3 Chimeric Antigen Receptor (CAR)-T (BHP01) in patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate CAR-T cell dose. Next, In dose expansion phase, patients were assign two…
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: Sichuan University • Aim: Cure
Last updated Jul 23, 2026 00:00 UTC
-
One pill may halt sleeping sickness spread
Disease control Recruiting nowThis protocol describes both the epidemiological study which aims at assessing whether over a three-year period a zero prevalence can be achieved when implementing a screen \& treat approach with acoziborole, as well as a nested clinical study aimed at generating further evidence…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Institute of Tropical Medicine, Belgium • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Cure Recruiting nowThe purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. · 601607 SSEResult impactLowLarge company Readout in ~3 moA large company. One readout moves the needle only so far.
-
Hepatitis b cure breakthrough? new combo aims for 50%+ cure rate
Cure Recruiting nowExploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overa…
Results expected Dec 2026 (estimated)
Phase 4 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Cure
Last updated Sep 03, 2026 00:00 UTC
-
Can a One-Time gene injection ease the burden of wet AMD?
Disease control Recruiting nowThis is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Results expected Jan 2027 (estimated)
Phase 1/2 • Sponsor: Skyline Therapeutics (US) Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Major RSV vaccine trial for seniors nears completion
Vaccine OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
Thinking your way to movement: brain-computer interface tested for hand function in tetraplegia
Disease control Recruiting nowThis prospective, multicenter, single-arm clinical trial will enroll subjects with tetraplegia secondary to spinal cord injury. An implantable brain-computer interface system for compensatory hand motor function will be used to reconstruct upper-limb function, so as to evaluate t…
Results expected Jan 2027 (estimated)
Sponsor: NeuroXess Technology (shanghai) Co.,Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can donor immune cells be engineered to fight blood cancer?
Cure Recruiting nowKCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.
Results expected Feb 2027 (estimated)
Phase 1 • Sponsor: University College, London • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
Could ketamine be a fast-acting lifeline for suicidal teens and young adults?
Symptom relief Recruiting nowKetamine, an NMDA antagonist, has been shown to have rapid anti- suicidal effects. However, its safety and efficacy and special populations has not been investigated and documented. Several reports in adults suggest rapid decrease of suicidal ideation. In the last decade there is…
Results expected Feb 2027 (estimated)
Phase 3 • Sponsor: Tatiana Falcone, MD • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Can a single eye injection restore sight in genetic blindness?
Cure OngoingThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects…
Results expected Mar 2027 (estimated)
Phase 1/2 • Sponsor: Ocugen • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~5 moA small company. This result carries real weight for it.
Ocugen · OCGN NASDAQ Trade on eToro (ad)Why investors are watching
Ocugen is a micro-cap company, so this Phase 1/2 trial of OCU400, a gene therapy for three inherited retinal diseases, is a core value driver. The trial tests safety and efficacy in 22 to 24 patients, and a positive readout could validate the therapy's broad approach across multiple mutations. For a company this size, the result of this small study carries outsized weight.
If it works: A positive safety and efficacy result could position OCU400 as a promising treatment for multiple forms of blindness, potentially attracting partners or funding. It could also support the company's path toward larger trials and eventual regulatory discussions.
If it fails: The trial could fail to show meaningful vision improvement or reveal safety problems, which would likely set the program back. Early-stage trials often fail, and a negative result for a micro-cap company could be severe, as the company has few other assets to fall back on.
AI-written from the trial record. Speculative, and not investment advice.
-
Can a single injection reprogram immune cells to fight cancer?
Cure Recruiting nowThis is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with…
Results expected Mar 2027 (estimated)
Phase 1 • Sponsor: Ruijin Hospital • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
One blood draw, many cancers: AI model aims to spot tumors early
Diagnosis Recruiting nowThis study is a multi-center, case-control study aiming at developing and blinded testing machine learning-based multiple cancers early detection model by prospectively collecting blood samples from newly diagnosed cancer patients and individuals without confirmed cancer diagnosi…
Results expected Oct 2026 (estimated)
Sponsor: Shanghai Weihe Medical Laboratory Co., Ltd. • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Engineered immune cells target CD5 in Hard-to-Treat T-Cell lymphomas
Cure Recruiting nowThis is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in …
Results expected Nov 2026 (estimated)
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Engineered immune cells target CD70 in kidney cancer
Cure OngoingThis is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Results expected Dec 2026 (estimated)
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~2 moA small company. This result carries real weight for it.
Adicet Bio · ACET NASDAQ Trade on eToro (ad)Why investors are watching
Adicet Bio runs this Phase 1/2 trial of ADI-270, an engineered gamma-delta CAR Vδ1 T cell therapy that targets CD70, in adults with relapsed or refractory clear cell renal cell carcinoma. The study tests dose escalation and dose expansion across 60 planned participants. For a micro-cap company, this readout carries the whole story: it is the main evidence that the platform works in patients.
If it works: A positive result could support further development of ADI-270 and draw partner or financing interest. It may also validate the company's engineered gamma-delta T cell approach beyond this one cancer.
If it fails: Early-phase trials often fail on safety, tolerability, or signs of benefit. A failure or delay could leave the company with limited clinical momentum and few other late-stage assets.
AI-written from the trial record. Speculative, and not investment advice.
-
Can a Three-Drug cocktail before surgery stop small cell lung cancer from returning?
Cure Recruiting nowThis is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer. Adebrelimab combined with chemotherapy for 4 cycles and apatinib mesylate for 3 cycles. Surgery was perform…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: Jin Ying • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Off-the-Shelf Gene-Edited immune cells tested against Hard-to-Treat lymphoma
Cure Recruiting nowThis is a single center, prospective, open-label, single-arm, phase 1/2 study for patients with r/r B-cell NHL to evaluate the safety and efficacy of gene edited allogenic CD19 CAR-γδT cells. The cells are from healthy adult volunteer donors that are gene edited ex vivo using CRI…
Results expected Dec 2026 (estimated)
Phase 1/2 • Sponsor: Chinese PLA General Hospital • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Engineered t cells target FLT3 in Hard-to-Treat leukemia
Cure Recruiting nowThis is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 18 evaluable adult and 18 evaluable pediatric subjects will be enrolled. Evaluable subjects are defined as those who have …
Results expected Jan 2027 (estimated)
Phase 1 • Sponsor: Hemogenyx Pharmaceuticals LLC • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Cervical smear DNA may reveal ovarian cancer years before symptoms
Diagnosis Recruiting nowHigh-grade serous ovarian carcinoma (HGSOC) is the deadliest gynaecological tumour. The 5-year overall survival rate for advanced-stage disease is less than 30 per cent, due to diagnosis at an advanced stage. There is currently no validated screening test for ovarian cancer. Acc…
Results expected Jan 2027 (estimated)
Sponsor: Institut Claudius Regaud • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Can adding radiation boost immunotherapy against spread head and neck cancer?
Disease control Recruiting nowStudy to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head \& neck cancers
Results expected Oct 2026 (estimated)
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could brain implants tame severe mental illness?
Disease control Recruiting nowThis is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of combo-stim deep brain stimulation for treatment-refractory mental disorders (obsessive-compulsive disorder, schizophrenia, bipolar with depression, anorexia nervosa, gambl…
Results expected Nov 2026 (estimated)
Sponsor: Shanghai Mental Health Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Womb transplants could let infertile women give birth
Disease control OngoingThis study aims to investigate the treatment of absolute uterine infertility (AUI) due to congenital or surgical absence of a uterus or presence of a nonfunctioning uterus. The investigators will follow a model based on a Swedish study to enroll 20 women with functioning ovaries …
Results expected Nov 2026 (estimated)
Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
Cure Recruiting nowEnrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFO…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
Cure Recruiting nowThis is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: New York Medical College • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
New TB vaccine aims to prevent active lung disease in adults
Vaccine OngoingThis study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active non-HIV-associated pulmonary tuberculosis. The study is di…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: Vaccine
Last updated Jul 08, 2026 00:00 UTC
-
Can whole blood beat component transfusions in trauma?
Disease control Recruiting nowThe goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who re…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on tough lymphomas
Disease control Recruiting nowDALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymp…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a targeted electric pulse therapy extend life in hard-to-treat pancreatic cancer?
Disease control Recruiting nowThis is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with locally advanced pancreatic cancer who have received three cycles of chemotherapy induction and have non-progressive disease will be enrolled. All patients …
Results expected Dec 2026 (estimated)
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Aiming to cure esophageal cancer without the knife
Cure OngoingThe present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment o…
Results expected Jan 2027 (estimated)
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
Can a Pre-Transplant drug keep leukemia from returning?
Disease control Recruiting nowThis is a prospective, multicenter, randomized controlled trial designed to evaluate whether short-term blinatumomab intensification before allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival outcomes in adults with high-risk BCR::ABL1-negative B-c…
Results expected Feb 2027 (estimated)
Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New mRNA vaccine aims to stop the stomach flu
Vaccine OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~5 moA large company. One readout moves the needle only so far.
-
Can a daily pill ease a stiff heart condition?
Disease control OngoingThe study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Meningitis b vaccine tested as gonorrhea shield in men
Prevention OngoingObjectives: Efficacy of a meningococcal vaccine against Neisseria gonorrhoea (NG) infection among men who have sex with men (MSM). Design: Parallel randomised double-blind placebo-controlled trial. Setting: A teaching hospital in Hong Kong. Participants: 150 adult MSM at risk …
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Chinese University of Hong Kong • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Experimental therapy offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowA Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.
Results expected Sep 2026 (estimated)
Phase 1 • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a Dual-Action antibody outsmart resistant tumors?
Disease control Recruiting nowGIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanc…
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a catheter valve replace Open-Heart surgery for a leaky heart valve?
Disease control OngoingThe TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The…
Results expected Sep 2026 (estimated)
Sponsor: P+F Products + Features USA Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
First human trial of Gene-Edited lung cells for rare breathing disorder
Disease control Recruiting nowThe major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophage…
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental vaccine combo takes on childhood brain cancer
Disease control Recruiting nowThis is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes fou…
Results expected Sep 2026 (estimated)
Phase 1 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
Why cures and vaccines come first here
We built this site so people can find trials that might cure them. These investor pages work toward the same goal from the money side: they show companies working on cures and vaccines first, and we promote those companies on purpose. We believe investor interest in cures and vaccines means more money for the companies chasing them, and more cure and vaccine trials as a result.
Nothing is hidden by this. Every trial soon ready, whatever its aim, is on the full list . Rankings are computed from the public trial record and the company's size. No company can pay to be listed or ranked higher.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. We think this page is more useful when you can go straight to somewhere that sells the stock, so the "Listed companies" view shows only companies our broker partner carries; switch to all sponsors for the unfiltered list. Ranking is never for sale: no company can pay to appear here or to place higher.